What is Brugada syndrome?

What is Brugada Syndrome

Brugada syndrome is an inherited cardiac channelopathy characterized by a distinctive coved-type ST-segment elevation ≥2 mm in right precordial leads V1 and/or V2 (positioned in the 2nd, 3rd, or 4th intercostal space) that predisposes patients to ventricular fibrillation and sudden cardiac death in the absence of structural heart disease 1.

Core Pathophysiology

Brugada syndrome represents a primary electrical disease affecting cardiac ion channels, most commonly involving the cardiac sodium channel gene (SCN5A), though this accounts for only 20-30% of genetically confirmed cases 2, 3. The syndrome affects structurally normal hearts—there are no macroscopic cardiac abnormalities on imaging or autopsy 2, 4.

The condition is inherited in an autosomal dominant pattern with marked sex and age-related penetrance: clinical manifestations occur predominantly in males (8:1 male-to-female ratio) and typically present in the third to fourth decades of life (mean age 41 ± 15 years), though events can occur at any age including neonates 1.

Epidemiology and Geographic Distribution

The prevalence ranges from 1 in 1,000 to 1 in 10,000, with significantly higher rates in Southeast Asia compared to Western countries 1. This geographic variation suggests both genetic and environmental factors influence disease expression.

Clinical Presentation and Risk Stratification

High-Risk Features

The syndrome manifests through life-threatening ventricular arrhythmias that characteristically occur during rest or sleep 1. The annual incidence of arrhythmic events varies dramatically by presentation:

• 13.5% per year in cardiac arrest survivors
• 3.2% per year in patients with syncope
• 1% per year in asymptomatic patients 1

Patients with spontaneous type 1 ECG pattern and syncope have a 6-fold higher risk of cardiac arrest compared to those without syncope 2.

Critical Triggers to Recognize

Several specific triggers unmask the type 1 ECG pattern and precipitate ventricular fibrillation 1, 3:

• Fever (requires aggressive antipyretic treatment)
• Excessive alcohol intake
• Large meals
• Sodium channel blocking drugs (comprehensive list at www.brugadadrugs.org)
• Certain psychotropic medications and anesthetic agents
• Cocaine use

Diagnostic Criteria

The diagnosis requires coved-type ST elevation with type 1 morphology ≥2 mm in one or more right precordial leads (V1 and/or V2), occurring either spontaneously or after provocative testing with intravenous sodium channel blockers (ajmaline, flecainide, procainamide, or pilsicainide) 1.

Important Diagnostic Nuances

• The ECG pattern can be intermittent—a single normal ECG does not exclude the diagnosis 2, 4
• High precordial lead placement (2nd and 3rd intercostal spaces) improves detection of type 1 pattern 3
• Only the type 1 pattern is diagnostic; types 2 and 3 are not sufficient for diagnosis 5
• Drug challenge testing should be terminated if ventricular arrhythmias, marked QRS widening, or type 1 pattern develops 3

Genetic Testing Limitations

Despite 12 genes being associated with Brugada syndrome, only SCN5A and CACN1Ac individually account for >5% of genotyped patients 1. Genetic testing yields positive results in only 20-30% of phenotype-positive patients, and a negative genetic test does not exclude the diagnosis 3, 5. Importantly, genotype status does not correlate with risk of adverse events and should not guide treatment decisions 3.

Management Approach

Mandatory Lifestyle Modifications for ALL Diagnosed Patients 1:

1. Avoid drugs listed at www.brugadadrugs.org
2. Avoid excessive alcohol intake and large meals
3. Prompt treatment of any fever with antipyretic drugs

Treatment Hierarchy Based on Risk

ICD implantation is the only proven therapy to reduce sudden cardiac death risk 1:

• Class I indication: Cardiac arrest survivors OR documented spontaneous sustained VT 1
• Class IIa indication: Spontaneous type 1 ECG pattern with history of syncope 1
• Class IIb indication: VF inducible during programmed ventricular stimulation with 2-3 extrastimuli 1

Alternative and Adjunctive Therapies

Quinidine should be considered for 1:

• Patients qualifying for ICD who have contraindications or refuse device
• Treatment of electrical storms
• Patients requiring treatment for supraventricular arrhythmias

Catheter ablation of abnormal epicardial areas in the right ventricular outflow tract may be considered for patients with electrical storms or repeated appropriate ICD shocks, though experience remains limited 1, 3.

Critical Clinical Pitfalls

1. Misinterpreting the type 1 Brugada pattern as incomplete right bundle branch block is a common and potentially fatal error 6
2. Syncope may be misdiagnosed as seizures/epilepsy, delaying appropriate cardiac evaluation 6
3. Family history does NOT predict individual risk—asymptomatic individuals with characteristic ECG but no family history are not necessarily low risk 2, 4, 2
4. Asymptomatic patients with drug-induced-only type 1 pattern (never spontaneous on repeated ECGs or 24-hour Holter) represent very low risk and do not require ICD if they adhere to behavioral recommendations 7
5. Electrophysiological testing remains controversial for risk stratification, with low positive predictive value (23%) but high negative predictive value (93%) over 3 years 2